Testing new antibody treatments for children with HIV in Botswana
Official title: A Clinical Trial of Three Broadly Neutralizing Antibodies and Analytic Treatment Interruption in Early-Treated Children in Botswana
Funded at Harvard School of Public Health · NIH-10920462 · Data updated 2026-11-12
This study is looking at a new treatment using special antibodies for children with HIV in Botswana, to see if it can help keep the virus under control without needing to take regular medication, making it easier for them during their important growth years.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harvard School of Public Health NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 5, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $2,095,803 |
| NIH project number | 5U01AI179561-02 |
| Project ID | NIH-10920462 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children aged 0-11 years who have been treated early for HIV.
✕Less likely to help
Patients who are not children or who have not received early treatment for HIV may not benefit from this research.
What this research studies
This research investigates the use of broadly neutralizing antibodies (bNAbs) as a treatment for children with HIV, aiming to reduce the need for traditional antiretroviral therapy (ART). The study will involve early-treated children in Botswana and will assess the effectiveness of these antibodies in maintaining viral suppression while minimizing the side effects associated with ART. Participants will undergo a carefully designed treatment interruption to evaluate the potential for long-term viral control without continuous medication. The approach is innovative and seeks to improve health outcomes during critical growth periods for young patients.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatment options for children with HIV, reducing their reliance on daily medications.
How similar studies have gone: Previous studies have shown promising results with similar antibody treatments, indicating potential for success in this novel approach.
Where this research is happening
-
Harvard School of Public Health
Boston, United States Active
Researchers
- Principal investigator: Shapiro, Roger L — Harvard School of Public Health
- Study coordinator: Shapiro, Roger L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.